- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02719171
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumab in Patients With Active Psoriatic Arthritis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Have psoriatic arthritis (PsA) symptoms for ≥ 6 months prior to screening, as assessed by the investigator
- Have PsA on the basis of the Classification Criteria for Psoriatic Arthritis (CASPAR) with peripheral symptoms at screening visit, as assessed by the investigator
- Have ≥ 5 tender joints and ≥ 5 swollen joints at screening and randomisation visits, as assessed by the investigator
- At least one psoriasis (PsO) lesion or a documented personal history of PsO at screening, as assessed by the investigator
- If patients receive concurrent PsA treatments, these need to be on stable doses
- Active PsA that has been inadequately controlled by standard doses of non-steroidal anti-inflammatory drugs (NSAIDs) administered for ≥ 4 weeks, or traditional disease-modifying anti-rheumatic drugs (DMARDs) (including sulfasalazine) administered for ≥ 3 months, or tumor necrosis factor inhibitor (TNFi) agents, or subjects are intolerant to NSAIDs or DMARDs or tumor necrosis factor inhibitor (TNFi) agents, as assessed by the investigator
Exclusion criteria:
- Major chronic inflammatory or connective tissue disease other than PsA (e.g. rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, Lyme disease, gout) and fibromyalgia, as assessed by the investigator
- Has received any therapeutic agent directly targeted to interleukin 12/23 (IL-12/23) (including ustekinumab), IL-23 or IL-17 (including secukinumab)
- Prior use of more than two different TNFi agents
- Use of the following treatments: TNFi agents within 12 weeks, etanercept within 8 weeks, leflunomide without cholestyramine wash-out within 8 weeks, systemic non-biologic medications for psoriatic arthritis or psoriasis and photochemotherapy within 4 weeks, intraarticular injections (including steroids) and intramuscular or intravenous corticosteroid treatment within 4 weeks, topical psoriasis medications and phototherapy within 2 weeks, low and high potency opioid analgesics within 2 weeks prior to randomisation
- Plans for administration of live vaccines during the study period or within 6 weeks prior to randomisation
- History of allergy/hypersensitivity to a systemically administered biologic agent or its excipients
- Active systemic infections during the last 2 weeks (exception: common cold) prior to randomisation, as assessed by the investigator
- Chronic or relevant acute infections including HIV, viral hepatitis and (or) active tuberculosis (TB). Patients with a positive QuantiFERON TB or purified protein derivate (PPD) test may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active TB.
- Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix
- Major surgery performed within 12 weeks prior to randomisation or planned within 32 weeks after randomisation (e.g. hip replacement, aneurysm removal, stomach ligation), as assessed by the investigator
- Total white blood count (WBC) < 3,000/µL, or platelets < 100,000/µL or neutrophils < 1,500/µL, or hemoglobin < 8.5 g/dL at screening
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2x the upper limit of normal, or serum direct bilirubin ≥ 1.5 mg/dL at screening
- Positive rheumatoid factor or anti-cyclic-citrullinated peptide (anti-CCP) antibodies at screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection every 4 weeks for 16 weeks.
|
Placebo for risankizumab administered by SC injection
|
Experimental: Risankizumab 150 mg Every 4 Weeks
Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection every 4 weeks for 16 weeks.
|
Risankizumab administered by SC injection
Other Names:
|
Experimental: Risankizumab 150 mg Weeks 0, 4, and 16
Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0, 4, and 16.
|
Risankizumab administered by SC injection
Other Names:
|
Experimental: Risankizumab 150 mg Weeks 0 and 12
Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 12.
|
Risankizumab administered by SC injection
Other Names:
|
Experimental: Risankizumab 75 mg Week 0
Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Week 0.
|
Risankizumab administered by SC injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 16
Time Frame: Week 16
|
Response defined by ACR20 criteria (improvement from baseline) at Week 16: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters:
Nonresponder imputation (NRI) was used for missing data. |
Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 16
Time Frame: Week 16
|
Response defined by ACR50 criteria (improvement from baseline) at Week 16: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters:
NRI was used for missing data. |
Week 16
|
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 16
Time Frame: Week 16
|
Response defined by ACR70 criteria (improvement from baseline) at Week 16: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters:
NRI was used for missing data. |
Week 16
|
Tender Joint Count (TJC68): Change From Baseline to Week 16
Time Frame: Baseline, Week 16
|
Sixty-eight joints were assessed and classified as either tender (1) or not tender (0).
A negative change represents a decrease in the number of tender joints.
|
Baseline, Week 16
|
Swollen Joint Count (SJC): Change From Baseline to Week 16
Time Frame: Baseline, Week 16
|
Sixty-six joints were assessed and classified as either swollen (1) or not swollen (0).
A negative change represents a decrease in the number of tender joints.
|
Baseline, Week 16
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Score: Change From Baseline to Week 16
Time Frame: Baseline, Week 16
|
The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities.
Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3).
Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability.
HAQ remission indicating normal physical function is defined by HAQ-DI score of < 0.5.
A negative change from Baseline indicates improvement.
|
Baseline, Week 16
|
Short Form-36 Health Status Survey (SF-36) Physical Component: Change From Baseline to Week 16
Time Frame: Baseline, Week 16
|
The SF-36 determined participant's overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health.
Items 1-4 comprise the physical component of the SF-36.
Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.
|
Baseline, Week 16
|
SF-36 Mental Component: Change From Baseline to Week 16
Time Frame: Baseline, Week 16
|
The SF-36 determined participant's overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health.
Items 5-8 comprise the mental component of the SF-36.
Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.
|
Baseline, Week 16
|
Dactylitis Count: Change From Baseline to Week 16 in Participants With Dactylitis at Baseline
Time Frame: Baseline, Week 16
|
The number of fingers and toes with dactylitis (ranging from 0 to 20).
A negative change represents a decrease in the number of fingers and toes affected by dactylitis.
|
Baseline, Week 16
|
Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Change From Baseline to Week 16 in Participants With Enthesitis at Baseline
Time Frame: Baseline, Week 16
|
Assessment of enthesitis was performed in the following 16 domains: left and right (L/R) medial epicondyle; L/R lateral epicondyle; L/R supraspinatus insertion into the greater tuberosity of humerus; L/R greater trochanter; L/R quadriceps insertion into superior border of patella; L/R patellar ligament insertion into inferior pole of patella or tibial tubercle; L/R Achilles tendon insertion into calcaneum; L/R plantar fascia insertion into calcaneum.
Tenderness at each site was classified as either absent (0) or present (1) to yield total SPARCC scores ranging from 0 (0 sites with tenderness) to 16 (16 sites with tenderness).
A negative change from Baseline indicates improvement.
|
Baseline, Week 16
|
Modified Nail Psoriasis Severity Index (mNAPSI): Change From Baseline to Week 16
Time Frame: Baseline, Week 16
|
mNAPSI grades each fingernail for onycholysis (separation of the nail plate from the nail bed) and oil-drop (salmon patch) dyschromia (reddish-brown discoloration under the nail plate) on a scale of 0 (none present) to 3 (>30% of the nail); pitting (small, sharply defined depressions in the nail surface) on a scale of 0 (0 pits present) to 3 (>50 pits present); nail plate crumbling on a scale of 0 (no crumbling) to 3 (>50% of nail has crumbling); and presence (1) or absence (0) of leukonychia (white spots), splinter hemorrhages, nail bed hyperkeratosis, and red spots in the lunula.
mNAPSI is calculated as the sum of all the components for all of the participants fingernails, for a minimal - maximal total score of 0 to 130.
A negative change from Baseline indicates improvement.
|
Baseline, Week 16
|
Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16
Time Frame: Week 16
|
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination.
The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked.
The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.
PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score.
The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100.
The percentage of participants achieving PASI90 at Week 16 are provided.
NRI was used for missing data.
|
Week 16
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Thakre N, D'Cunha R, Goebel A, Liu W, Pang Y, Suleiman AA. Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis. Rheumatol Ther. 2022 Dec;9(6):1587-1603. doi: 10.1007/s40744-022-00495-0. Epub 2022 Sep 30.
- Mease PJ, Kellner H, Morita A, Kivitz AJ, Aslanyan S, Padula SJ, Topp AS, Eldred A, Behrens F, Papp KA. Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial. Rheumatol Ther. 2022 Oct;9(5):1361-1375. doi: 10.1007/s40744-022-00474-5. Epub 2022 Aug 5.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M16-002
- 2015-003625-34 (EudraCT Number)
- 1311.5 (Other Identifier: Boehringer Ingelheim)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Psoriatic
-
AmgenRecruitingActive Juvenile Psoriatic ArthritisSpain, United Kingdom, Turkey, Belgium, France, Greece, Italy, Austria, Germany, Netherlands, Poland, Portugal, Romania, Lithuania, South Africa
-
Universitätsklinikum Hamburg-EppendorfBristol-Myers Squibb; Eli Lilly and Company; UCB Pharma; Merck Sharp & Dohme LLC; AbbVi... and other collaboratorsRecruiting
-
Bristol-Myers SquibbCompletedPsoriatic Arthritis (PsA)Germany
-
Pope Research CorporationAmgenWithdrawn
-
Sun Pharmaceutical Industries LimitedActive, not recruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Germany, India, Japan, Korea, Republic of, Poland, Spain
-
AbbVieActive, not recruitingPsoriatic Arthritis (PsA)United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
-
Sun Pharmaceutical Industries LimitedCompleted
-
Bristol-Myers SquibbCompletedActive Psoriatic ArthritisSpain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
-
Sun Pharmaceutical Industries LimitedRecruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Estonia, Korea, Republic of, Poland, Slovakia, Spain, Taiwan, Germany, Italy, India, Canada
-
Humanis Saglık Anonim SirketiCompletedPsoriasis and Psoriatic ArthritisIndia
Clinical Trials on placebo for risankizumab
-
AbbVieActive, not recruitingCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
-
AbbVieCompletedRisankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)PsoriasisRussian Federation
-
AbbVieCompletedCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
-
AbbVieCompletedUlcerative Colitis (UC)United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Nether... and more
-
AbbVieRecruitingScalp Psoriasis | Genital PsoriasisUnited States
-
AbbVieCompletedPsoriasisUnited States, Canada, Puerto Rico, Spain
-
AbbVieCompletedCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Ireland, Israel, Italy, Korea, Republic... and more
-
AbbVieRecruitingCrohn's DiseaseUnited States, Canada, Israel, Taiwan, Japan, Korea, Republic of
-
AbbVieCompletedHidradenitis SuppurativaUnited States, Australia, Canada, France, Germany, Japan, Netherlands, Spain
-
AbbVieBoehringer IngelheimCompleted